CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 356 enrolled
Drug / intervention
Decipher Prostate Cancer Classifierother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02783950
NCT02783950N/ACompleted
CompareCT.gov

Genomics in Michigan Impacting Observation or Radiation (G-MINOR)

University of Michigan Rogel Cancer Center·interventional·Posted May 26, 2016·Updated Sep 26, 2024

In Brief

A clinical study evaluating Decipher Prostate Cancer Classifier for Prostate Cancer. Completed, enrolled 356 participants across 13 sites.

Detailed Summary

To determine the impact of Decipher test results on adjuvant treatment decisions of high-risk post-RP patients with undetectable post-op prostate specific antigen (PSA) compared to clinical factors alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsMichigan Urological Surgery Improvement Collaborative (MUSIC), GenomeDx Biosciences Corp

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMay 26, 2016
Enrollment StartJan 17, 2017
Primary CompletionFeb 1, 2020
Study CompletionApr 2, 2024
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 10.1 years ago

Interventions

Decipher Prostate Cancer Classifierother

The Decipher test (GenomeDx Biosciences, San Diego, CA) is a genomic test that predicts high grade disease, the probability of metastasis and prostate cancer-specific mortality for men with prostate cancer.